{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:07Z","timestamp":1786980487931,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s10067-005-0008-1","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T03:39:59Z","timestamp":1128051599000},"page":"430-432","source":"Crossref","is-referenced-by-count":20,"title":["Lethal acute respiratory distress syndrome during anti-TNF-\u03b1 therapy for rheumatoid arthritis"],"prefix":"10.1007","volume":"25","author":[{"given":"Christian","family":"Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Beiderlinden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,10,1]]},"reference":[{"key":"8_CR1","first-page":"101","volume":"71","author":"AP Cairns","year":"2002","unstructured":"Cairns AP, Taggart AJ (2002) Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 71:101\u2013105","journal-title":"Ulster Med J"},{"key":"8_CR2","first-page":"S77","volume":"44","author":"L Klareskog","year":"2001","unstructured":"Klareskog L, Moreland LM, Bohen SB et al (2001) Global safety and efficacy of up to five years of etanercept (Enbrel) therapy. Arthritis Rheum 44:S77 (abstract no. 150)","journal-title":"Arthritis Rheum"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","volume":"42","author":"S Kroesen","year":"2003","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF alpha therapy. Rheumotology 42:617\u2013621","journal-title":"Rheumotology"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hydrich","year":"2004","unstructured":"Hydrich KL, Silmann AJ, Watson KD, Symmons DPM (2004) Anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538\u20131543","journal-title":"Ann Rheum Dis"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls\u2014a population based study. Arthritis Rheum 46:2287\u20132293","journal-title":"Arthritis Rheum"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Gall Le","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study. JAMA 270:2957\u20132963","journal-title":"JAMA"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00054725-200111000-00009","volume":"7","author":"MA Ritz","year":"2001","unstructured":"Ritz MA, Jost R (2001) Severe pneumococcal pneumonia following treatment with Infliximab for Crohn's disease. Inflamm Bowel Dis 7:327","journal-title":"Inflamm Bowel Dis"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0025-6196(11)62418-X","volume":"76","author":"M Baghai","year":"2001","unstructured":"Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL (2001) Fatal sepsis with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 76:653\u2013656","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"8_CR9","first-page":"38","volume":"61","author":"DF Sabath","year":"2002","unstructured":"Sabath DF, Holman J, Wallis WJ (2002) Serious infection reports with etanercept (Enbrel) therapy. Ann Rheum Dis 61(Suppl 1):38 (abstract no. 0P0099)","journal-title":"Ann Rheum Dis"},{"key":"8_CR10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, Van Der Heijde D, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/ajrccm.155.2.9032201","volume":"155","author":"T Poll Van Der","year":"1997","unstructured":"Van Der Poll T, Keogh CV, Buurman WA, Lowry SF (1997) Passive immunization against tumor necrosis factor-alpha impairs host defence during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 155:603\u2013608","journal-title":"Am J Respir Crit Care Med"},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00012","volume":"62","author":"CR Culy","year":"2002","unstructured":"Culy CR, Keating GM (2002) Etanercept. An update review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493\u20132537","journal-title":"Drugs"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00001432-200304000-00012","volume":"16","author":"JJ Osterheert","year":"2003","unstructured":"Osterheert JJ, Bonten MJM, Hak E et al (2003) Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 16:153\u2013159","journal-title":"Curr Opin Infect Dis"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/rheumatology\/keh167","volume":"43","author":"SA Wright","year":"2004","unstructured":"Wright SA, Taggart AJ (2004) Pneumococcal vaccination for RA patients on TNF-\u03b1 antagonists. Rheumatology 43:523","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-005-0008-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0008-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:42:42Z","timestamp":1559104962000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-005-0008-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s10067-005-0008-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}